Indoximod + Temozolomide + Cyclophosphamide + Etoposide + Lomustine
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glioblastoma
Conditions
Glioblastoma, Medulloblastoma, Ependymoma, Diffuse Intrinsic Pontine Glioma
Trial Timeline
Oct 2, 2019 → Oct 2, 2027
NCT ID
NCT04049669About Indoximod + Temozolomide + Cyclophosphamide + Etoposide + Lomustine
Indoximod + Temozolomide + Cyclophosphamide + Etoposide + Lomustine is a phase 2 stage product being developed by Johnson & Johnson for Glioblastoma. The current trial status is active. This product is registered under clinical trial identifier NCT04049669. Target conditions include Glioblastoma, Medulloblastoma, Ependymoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04049669 | Phase 2 | Active |
Competing Products
20 competing products in Glioblastoma